Trial reportJournal of neuro-oncology2018
Ganglioglioma in children and young adults: single institution experience and review of the literature.
Trial report in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- A Clinicoradiological Series of 39 Gangliogliomas: Insights into Surgical Outcomes and Prognostic Factors.Neurosurgery practice · 2026Article
- Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults.CNS oncology · 2024Review
- Extra-temporal pediatric low-grade gliomas and epilepsy.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Incidence and survival characteristics of pediatric ganglioglioma from 2004 to 2018, with focus on infratentorial sites.Neuro-oncology practice · 2024Article
- Long-term epilepsy associated-tumors (LEATs): what is new?Arquivos de neuro-psiquiatria · 2023Article
- The clinicopathological features of ganglioglioma with CD34 expression and BRAF mutation in patients with epilepsy.Frontiers in molecular neuroscience · 2023Article
- The clinical and pathological features of low-grade epilepsy-associated glioneuronal tumors.Scientific reports · 2022Article
- Ganglioglioma with novel molecular features presenting in a child with Allan-Herndon-Dudley syndrome.BMJ case reports · 2022Article
- Seizure outcomes and prognostic factors in patients with gangliogliomas associated with epilepsy.Frontiers in surgery · 2022Article
- Case report:Frontiers in medicine · 2022Article
- Imaging of brain tumors in children: the basics-a narrative review.Translational pediatrics · 2021Review
- A Rare Case of a Congenital Nasopharyngeal Ganglioglioma With Dyspnea in a 1-Month-Old Male Infant: A Case Report.Frontiers in pediatrics · 2021Article
- Low-grade gangliogliomas in adults: A population-based study.Cancer medicine · 2021Article
- Low-grade developmental and epilepsy associated brain tumors: a critical update 2020.Acta neuropathologica communications · 2020Review
- Clinicopathologic Features of Diencephalic Neuronal and Glioneuronal Tumors.Journal of neuropathology and experimental neurology · 2020Article
- Suprasellar ganglioglioma presenting as a middle cerebral artery infarction.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019Article
- Prolonged Response Induced by Single Agent Vemurafenib in aFrontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGanglioglioma (GG) is a rare mixed glial-neuronal neoplasm accounting for 0.5-5% of all pediatric central nervous system (CNS) tumors. Rarity of this tumor has precluded defining robust treatment guidelines. This retrospective study evaluates the prognostic factors and outcomes of this rare neoplasm. PATIENTS AND
methodsRetrospective analysis of 55 patients with GG was conducted to describe clinical findings, and outcomes. Kaplan-Meier survival and Cox-regression analyses were performed to assess the overall survival (OS) and progression-free survival (PFS).
resultsThe mean age at diagnosis was 11.8 years (range 1-21 years) with a median follow-up period of 9.5 years. 53 patients (92.7%) had low grade GG and 2 patients had anaplastic GG. 25 patients had tumor progression, whose median PFS was 12 years. Six patients with low grade GG progressed to a higher grade, with median survival of 9.1 month after transformation. The 5 and 10 year PFS were 65 and 57%, respectively. The 5 and 10 year OS was 96 and 86% respectively. 8 of the 19 (42%) samples tested demonstrated positivity for the BRAF V600E mutation. Multivariate Cox regression analyses showed location and extent of resection were significant factors for PFS and presence of metastatsis attained significance for OS.
conclusionThis is the one of the largest retrospective study of pediatric GG. Identifying clinical variables, which could stratify these tumors into low- and high-risk groups might help to profile a risk-based therapeutic strategy. Collaborative multiinstitutional prospective studies are warranted to delineate treatment consensus and investigate prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.